

Special Issue

CDK Targeting in Cancer Therapy

Message from the Guest Editor

The aim of this Special Issue is to present a collection of both original studies and/or reviews, at the preclinical and clinical level, on the use of CDK inhibitors as an antitumoral strategy, to provide insights into their molecular mechanisms of action and possible resistance mechanisms. Specific sub-topics covered may include, but are not limited to, the following:

- Evaluation of the efficacy of CDK inhibitors in solid tumor models, as a single treatment, or in combination with other target agents, immunotherapy, or chemotherapy;
- Identification of specific biomarkers of responsiveness;
- Mechanisms of resistance to CDK inhibitors which inevitably limit their clinical benefit, and strategies to overcome such resistance.

Guest Editor

Prof. Dr. Mara A. Bonelli

Department of Medicine and Surgery, University of Parma, Via Gramsci, 14-43125 Parma, Italy

Deadline for manuscript submissions

closed (31 January 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/96766

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)